Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)
Status:
Completed
Trial end date:
2021-02-26
Target enrollment:
Participant gender:
Summary
Phase IV study to evaluate the effectiveness of additional inhaled sargramostim (GM-CSF)
versus standard of care on blood oxygenation in patients with COVID-19 coronavirus infection
and acute hypoxic respiratory failure.